Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and bariatric metabolic surgery (BMS) are well established treatments for diabetes and obesity, but their comparative effectiveness for the prevention of ORC is unknown. The gene discussed is GLP1R; the disease is diabetes mellitus.